Your browser is no longer supported. Please, upgrade your browser.
ABBV AbbVie Inc. daily Stock Chart
AbbVie Inc.
IndexS&P 500 P/E59.99 EPS (ttm)1.12 Insider Own0.10% Shs Outstand1.59B Perf Week-4.04%
Market Cap107.04B Forward P/E13.43 EPS next Y5.00 Insider Trans-9.15% Shs Float1.57B Perf Month0.39%
Income1.82B PEG4.03 EPS next Q1.05 Inst Own72.70% Short Float5.50% Perf Quarter15.73%
Sales20.44B P/S5.24 EPS this Y-57.20% Inst Trans-0.28% Short Ratio7.98 Perf Half Y1.66%
Book/sh0.86 P/B78.13 EPS next Y18.05% ROA6.50% Target Price74.00 Perf Year22.76%
Cash/sh4.97 P/C13.51 EPS next 5Y14.90% ROE56.00% 52W Range50.19 - 70.75 Perf YTD4.30%
Dividend2.04 P/FCF98.74 EPS past 5Y-17.80% ROI16.80% 52W High-3.43% Beta-
Dividend %3.04% Quick Ratio1.30 Sales past 5Y7.00% Gross Margin79.40% 52W Low36.11% ATR1.28
Employees26000 Current Ratio1.40 Sales Q/Q10.50% Oper. Margin21.50% RSI (14)52.80 Volatility2.42% 1.69%
OptionableYes Debt/Eq11.09 EPS Q/Q4.90% Profit Margin8.90% Rel Volume0.57 Prev Close67.19
ShortableYes LT Debt/Eq7.76 EarningsJul 24 BMO Payout155.30% Avg Volume10.82M Price68.32
Recom2.30 SMA200.14% SMA502.64% SMA20010.04% Volume5,197,587 Change1.68%
Jun-17-15Initiated Piper Jaffray Overweight
Jun-08-15Reiterated Jefferies Buy $86 → $90
May-28-15Resumed Morgan Stanley Equal-Weight $72
May-27-15Resumed JP Morgan Overweight $75
Jan-06-15Reiterated UBS Buy $72 → $76
Nov-26-14Reiterated Argus Buy $65 → $85
Nov-14-14Initiated Deutsche Bank Buy $80
Jul-28-14Upgrade UBS Neutral → Buy $57 → $67
Jun-24-14Reiterated Argus Buy $59 → $65
Jan-06-14Reiterated UBS Neutral $46 → $56
Oct-29-13Reiterated Argus Buy $52 → $59
Aug-12-13Initiated Argus Buy $52
May-15-13Reiterated R. F. Lafferty Buy $47.90 → $61
Apr-29-13Reiterated Barclays Equal Weight $41 → $44
Apr-15-13Reiterated Barclays Equal Weight $37 → $41
Jun-30-15 01:18PM  Citigroup Still Says Sell AbbVie at
Jun-29-15 02:44PM  Evercore ISI Analyst Breaks Down Amgen's IPR Against AbbVie's Humira Formulation Patent
12:00PM  Activist investors love spin-offs. Heres why you should, too at Fortune
08:07AM  Better Dividend Stock: AbbVie or Johnson & Johnson? at Motley Fool
Jun-27-15 06:32PM  WEEKEND VIDEO: Market Positives and Negatives
Jun-26-15 12:50PM  Gilead Sciences: New Scripts for Harvoni/Sovaldi Decelerating at
11:35AM  Is Big Pharma Advertising Getting Out of Control? at 24/7 Wall St.
Jun-24-15 05:19PM  Intrexon, Enanta Among Top Biotech New Issues at Investor's Business Daily
08:00AM  Hep C treatment succeeds in late stage study
07:12AM  AbbVie hepatitis C cocktail succeeds in late-stage study Reuters
06:00AM  AbbVie Announces New Phase 3b Results in Genotype 1b Chronic Hepatitis C Patients with Compensated Liver Cirrhosis PR Newswire
Jun-23-15 05:02PM  Veteran Investor Sam Isaly Picks Top Biotechs at
01:21PM  Entrepreneurs Will Enter the Dragons' Den at CompTIA ChannelCon 2015 PR Newswire
10:48AM  Obamacare ruling, Taylor Swift's Apple saga, and Amazon still selling Confederate flag
Jun-22-15 07:30PM  Are These 3 Biotech Stocks Dirt Cheap? at Investopedia
01:56PM  AbbVie: 'Still Our Favorite Large-Cap Pharma Name' at
Jun-19-15 01:18PM  Gilead Sciences: New Harvoni Prescriptions Decelerate at
Jun-18-15 07:00PM  Chi-Med Arthritis Drug Spurs Interest From Potential Partners at Bloomberg
05:01PM  AbbVie Declares Quarterly Dividend PR Newswire
Jun-17-15 04:43PM  Deerfield Management Bets Big On Company It Polished Ahead Of IPO, Nivalis Therapeutics Inc (NVLS) at Insider Monkey
12:21PM  Why Bristol-Myers Squibb Could Fall Nearly 10% at
07:06AM  Coverage initiated on AbbVie by Piper Jaffray
Jun-15-15 12:37PM  Jefferies Recommends 21 Stocks for the Next Six Months and Beyond at TheStreet
11:35AM  AbbVie creates new position to expand global philanthropy at
09:15AM  Jefferies Franchise Stock Picks Crush S&P 500: 4 to Buy Now at 24/7 Wall St.
01:36AM  AbbVie and Galapagos present cystic fibrosis corrector and potentiator screening approach at ECFS conference GlobeNewswire
01:33AM  AbbVie and Galapagos present cystic fibrosis corrector and potentiator screening approach at ECFS conference Thomson Reuters ONE
Jun-12-15 09:00AM  AbbVie to Present Data from Studies of DUOPA® (carbidopa and levodopa) Enteral Suspension in Advanced Parkinson's Disease During the International Congress of Parkinson's Disease and Movement Disorders PR Newswire
02:30AM  Phase 1b Study of Investigational Treatment Venetoclax with Rituximab Shows Clinical Response in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia PR Newswire
Jun-11-15 06:57PM  Cramer: Massive biotech moves that make sense at CNBC
04:01PM  Prisoners Sue Massachusetts for Withholding Hepatitis C Drugs at The Wall Street Journal
01:13PM  Why Drugmaker AbbVie Can Power Past Patent Expiration at Investor's Business Daily
Jun-10-15 12:32PM  Spinning Right Round: New Spin-Off ETF Debuts
10:32AM  Desperate Parents Of Autistic Children Trying Cannabis Despite Lack Of Studies at Forbes
08:07AM  'Spending On These 10 Drugs Could Cost Taxpayers $50 Billion'--Is That Bad For Patients? at Forbes
Jun-09-15 12:30PM  Insiders and Hedge Funds Were Right About Halozyme Therapeutics, Inc. (HALO); Now They Are Buying More at Insider Monkey
Jun-08-15 06:22PM  Skyworks, Nike Among Big Cap 20 Stocks Pulling Back at Investor's Business Daily
04:43PM  10 drugs to hit fed budget by $50B over decade at CNBC
02:03PM  This Technology Could Disrupt U.S. Pharma Stocks, Credit Suisse Says
01:00PM  Autoimmune Drugs to Drive Big Pharma Higher in Coming Years at 24/7 Wall St.
10:30AM  Why prescription drugs cost so much
08:00AM  AbbVie Mobilizes 3,100 Employees for Week of Service Projects to Transform Schools and Communities Globally PR Newswire
Jun-05-15 04:00PM  AbbVie to Present at Goldman Sachs 36th Annual Global Healthcare Conference PR Newswire
03:15PM  AbbVie Reports Positive Results on Oncology Drug Imbruvica - Analyst Blog
Jun-04-15 11:58AM  2015 Global 2000: The World's Largest Drug And Biotech Companies at Forbes
09:50AM  Halozyme-AbbVie Ink Deal for ENHANZE Platform, Shares Up - Analyst Blog
09:20AM  Ibrutinib (IMBRUVICA®) Improved Survival for Treatment-Naive Chronic Lymphocytic Leukemia Patients in Phase III RESONATE-2 Trial PR Newswire
07:00AM  AbbVie's Research in Immunology to be Featured at the European League Against Rheumatism Annual Congress (EULAR) 2015 PR Newswire
Jun-03-15 03:28PM  Halozyme Stock Hits New High On AbbVie Collaboration at Investor's Business Daily
01:32PM  Hedge Funds Hate These 5 Stocks -- but Should You? at TheStreet
11:34AM  Biotech Stock Roundup: ImmunoGen Soars on ASCO Data, Amgen Collaborates with Roche - Analyst Blog
10:30AM  How Halozyme Will Continue to Grow With Its New Deal at 24/7 Wall St.
09:14AM  Halozyme Reaches Collaboration Deal With AbbVie at The Wall Street Journal
08:30AM  Halozyme Enters Into Global Collaboration and Licensing Agreement With AbbVie PR Newswire
Jun-02-15 10:45AM  Adding Investigational Agent Elotuzumab to Standard Treatment for Multiple Myeloma Significantly Reduced the Risk of Disease Progression, According to New Phase III Data from ELOQUENT-2 Trial Published in New England Journal of Medicine Business Wire
08:50AM  The 4 Overlooked Winners of ASCO at 24/7 Wall St.
Jun-01-15 02:20PM  AbbVie Presents Positive Data from Multiple Studies at ASCO - Analyst Blog
12:22PM  AbbVie to Present at Jefferies 2015 Healthcare Conference PR Newswire
09:38AM  UBS Reviews ASCO, Notes Weekend Data Points From 2 Companies
08:00AM  AbbVie Presents Phase 2 Results from Study of Investigational Medicine Veliparib in Patients with Non-Small Cell Lung Cancer at the American Society of Clinical Oncology Annual Meeting PR Newswire
May-31-15 09:05AM  Ibrutinib (IMBRUVICA®) Phase Ib/II Data Show Promise in Patients with Chronic Graft-Versus-Host-Disease PR Newswire
09:01AM  Analysis of Phase III RESONATE Data Shows Adherence to the Recommended 420mg Dose of IMBRUVICA® (ibrutinib) Results in Improved Efficacy Benefits in Patients with Chronic Lymphocytic Leukemia PR Newswire
08:00AM  AbbVie Presents Results from Phase 1 Studies of Investigational Compound Venetoclax in Patients with Multiple Myeloma at the American Society of Clinical Oncology Annual Meeting PR Newswire
May-30-15 07:31AM  Phase III HELIOS Study Results Show Ibrutinib (IMBRUVICA®) Combination Therapy Significantly Increased Progression-Free Survival in Previously-Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Patients PR Newswire
May-29-15 02:15PM  Gilead's New HIV Combination Drug under Review in the EU - Analyst Blog
01:23PM  Deerfield Managements Top Health Stocks ~ Auspex Pharmaceuticals Inc (ASPX), Horizon Pharma PLC (HZNP), AbbVie Inc (ABBV) at Insider Monkey
11:51AM  This stock is no longer in the Top 20 most held at CNBC
May-28-15 03:11PM  Pfizer: Split Decision Could Come Earlier Than You Think at
02:51PM  AbbVie: The Future's So Hazy I Can't Wear Shades at
12:01PM  AbbVie (ABBV) Stock Is the 'Chart of the Day' at TheStreet
11:26AM  Breakout Watch: AbbVie Testing New Buy Point at Investor's Business Daily
09:42AM  How to Trade 3 of the Market's Most Active Stocks at TheStreet
09:30AM  Short Sellers More Selective on Big Pharma Stocks at 24/7 Wall St.
09:00AM  Ibrutinib (IMBRUVICA®) in Combination with Anti-PD-L1 Antibody (MEDI4736) Study Commences for Patients with Two Relapsed/Refractory Blood Cancers PR Newswire
08:56AM  Pharmalot.. Pharmalittle.. Good Morning: We're Catching up on J&J, AbbVie, Teva and Lots More!! at The Wall Street Journal
08:52AM  Morgan Stanley Calls AbbVie 'Unpredictable' With 'Upside'
May-27-15 06:59PM  IBD Market Wrap - 05/27/15
01:12PM  AbbVie Is Buying Back $5 Billion in Stock. Hurray? at Insider Monkey
11:42AM  AbbVie (ABBV) Stock Gains on Bullish JPMorgan Note at TheStreet
10:37AM  JPMorgan: Buy AbbVie, Low Valuation Belies EPS Growth Potential at
06:55AM  AbbVie Accelerates Share Buybacks at The Wall Street Journal
06:05AM  ABBVIE INC. Files SEC form 8-K, Other Events
May-26-15 07:00PM  AbbVie Presents New Data for its Investigational Hepatitis C Treatment in Japanese Patients With and Without Cirrhosis PR Newswire
05:36PM  NWQ's First-Quarter Buys and Adds Affect Portfolio
04:31PM  Ambarella Leads 3 Top Stocks Bucking The Sell-Off
02:27PM  Jim Cramer -- Here's Why I'm Buy, Buy, Buying J&J and Selling Merck at TheStreet
01:21PM  This Medical Stock Refuses To Fall With Major Stock Indexes at Investor's Business Daily
12:42PM  AbbVie (ABBV) Stock Gains After Completing $21 Billion Pharmacyclics Purchase at TheStreet
11:15AM  Abbvie completes $21 billion buyout of Pharmacyclics
08:51AM  ABBVIE INC. Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Other Events, Financial Statement
08:30AM  AbbVie Completes Acquisition of Pharmacyclics PR Newswire
May-22-15 09:15AM  Jefferies Makes Changes to Top Pharmaceutical Stocks to Buy at 24/7 Wall St.
08:00AM  AbbVie Announces Expiration of Hart-Scott-Rodino Waiting Period for AbbVie's Acquisition of Pharmacyclics PR Newswire
May-21-15 12:12PM  Abbvie specifies breakdown of $21 billion Pharmacyclics deal
08:27AM  What Does The Johnson & Johnson/Achillion Deal Mean For HCV Competitors?
08:00AM  AbbVie Announces Offer Consideration for Acquisition of Pharmacyclics PR Newswire
May-20-15 03:34PM  Glenview Repeats AbbVie Bull Stance, Shuts Fund To Newbies
May-19-15 10:08AM  Healthcare AM Winners and Losers: May 19, 2015
09:15AM  Pharmacyclics (PCYC), DIRECTV (DTV), Actavis (ACT): Farallon Capital Betting On Merger Arb Plays at Insider Monkey
May-18-15 06:16PM  Cramer: Merger mania-Buckle up for more! at CNBC
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company's products include HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; VIEKIRA PAK, an all-oral, short-course, interferon-free therapy, with or without ribavirin, for adult patients with genotype 1 chronic hepatitis, including those with compensated cirrhosis; Kaletra, an anti-HIV-1 medicine used with other anti-HIV-1 medications as a treatment that maintains viral suppression in people with HIV-1; Norvir, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1 infection; and Synagis to prevent respiratory syncytial virus infection in high risk infants. It also provides AndroGel, a testosterone replacement therapy for males diagnosed with symptomatic low testosterone; Creon, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid to treat hypothyroidism; and Lupron, a product for the palliative treatment of prostate cancer, and the treatment of endometriosis and central precocious puberty, as well as for the preoperative treatment of patients with anemia. In addition, the company offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Sevoflurane, an anesthesia product for human use; TriCor, Trilipix, Niaspan, Simcor, and Advicor to treat metabolic conditions characterized by high cholesterol and/or high triglycerides; and Zemplar to treat secondary hyperparathyroidism. It sells its products to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers from its distribution centers and public warehouses. The company has strategic collaboration with Calico Life Sciences LLC, Infinity Pharmaceuticals, Inc., Ablynx NV, Galapagos NV, Alvine Pharmaceuticals, Inc., and Action Pharma A/S. AbbVie Inc. was incorporated in 2012 and is based in North Chicago, Illinois.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
HURWICH THOMAS A.VP, ControllerMay 19Option Exercise22.946,200142,23274,660May 21 05:50 PM
HURWICH THOMAS A.VP, ControllerMay 19Sale66.006,200409,20068,460May 21 05:50 PM
GONZALEZ RICHARD AChairman of the Board and CEOApr 28Option Exercise35.88175,4776,296,115657,624Apr 30 06:01 PM
GONZALEZ RICHARD AChairman of the Board and CEOApr 28Sale64.6795,9706,206,473554,660Apr 30 06:01 PM
GONZALEZ RICHARD AChairman of the Board and CEOApr 28Sale64.928,281537,569482,147Apr 30 06:02 PM
GONZALEZ RICHARD AChairman of the Board and CEOApr 08Sale64.726,994452,652561,360Apr 30 06:01 PM
Schumacher Laura JEVP, Bus.Dev.,Ext.Aff.&GCMar 02Sale60.3025,0001,507,500274,116Mar 03 06:10 PM
RICHMOND TIMOTHY J.SVP, Human ResourcesMar 02Sale60.3012,314742,534106,954Mar 03 06:07 PM
RICHMOND TIMOTHY J.SVP, Human ResourcesFeb 27Sale60.512,074125,492123,860Mar 03 06:07 PM
HURWICH THOMAS A.VP, ControllerFeb 27Sale60.571,18571,77770,322Mar 03 06:06 PM
SALEKI-GERHARDT AZITASVP, OperationsFeb 27Sale60.472,112127,706104,555Mar 03 06:09 PM
RICHMOND TIMOTHY J.SVP, Human ResourcesFeb 17Sale58.7024114,147106,592Feb 19 05:51 PM
SALEKI-GERHARDT AZITASVP, OperationsFeb 09Option Exercise24.072,25054,1643,168Feb 11 05:28 PM
CHASE WILLIAM JEVP, Chief Financial OfficerDec 22Option Exercise24.078,495204,501188,563Dec 22 05:22 PM
CHASE WILLIAM JEVP, Chief Financial OfficerDec 22Sale68.008,495577,660180,068Dec 22 05:22 PM
HURWICH THOMAS A.VP, ControllerNov 24Sale67.811,500101,71763,211Nov 26 05:00 PM
HURWICH THOMAS A.VP, ControllerNov 06Option Exercise24.0710,000240,73171,448Nov 07 05:57 PM